TORONTO, Feb. 8 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will participate as a presenter and panelist at the 10th Annual BIO CEO & Investor Conference. Dr. Ezrin will provide an update on the Company’s preparations for the planned Phase III trial for Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer. The conference is being held at the Waldorf Astoria Hotel in New York City and Bradmer’s corporate presentation is scheduled on Tuesday, February 12th at 2:45 PM ET in the Bleekman Suite. Dr. Ezrin will also be a panelist at the Neuro-Oncology Workshop, Neuro-oncology: “Breaking Down the Barriers to New Neuro-Oncology Drugs” session on Monday, February 11th from 9:30 to 10:55 AM ET in the East Foyer.
For more information on the BIO CEO & Investor Conference, visit the conference website at http://ceo.bio.org.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
CONTACT: Bradmer Pharmaceuticals Inc.: Mr. Brian Brohman, Chief Business
Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com; Investor
Relations: Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700
(Ext. 238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com
